Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT06494878
PHASE3

The PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity

Sponsor: University of Calgary

View on ClinicalTrials.gov

Summary

The goal of the PARTUM trial is to determine if taking low-dose aspirin daily for 6 weeks after delivery is similar (non-inferior) to usual care low-molecular-weight heparin injections to prevent venous thromboembolism (VTE: blood clots in the legs or lungs) for postpartum individuals with VTE risk factors.

Official title: The PARTUM (Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity) Trial

Key Details

Gender

FEMALE

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

8805

Start Date

2025-04

Completion Date

2030-12

Last Updated

2025-03-03

Healthy Volunteers

No

Interventions

DRUG

Aspirin

75-100 mg taken once daily by mouth.

DRUG

Low-molecular-weight heparin

Low-molecular-weight heparin injections daily as prescribed by the treating physician.

Locations (3)

Foothills Medical Centre

Calgary, Alberta, Canada

The Ottawa Hospital - General Campus

Ottawa, Ontario, Canada

Mount Sinai Hospital

Toronto, Ontario, Canada